Relmada Therapeutics Inc (RLMD)

May 05, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network

May 05, 2026

May 05, 2026

Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan

May 05, 2026

May 05, 2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - GlobeNewswire Inc.

May 05, 2026

May 04, 2026

Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD) - Stock Titan

May 04, 2026

May 01, 2026

Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN

May 01, 2026

Apr 23, 2026

Relmada Therapeutics (RLMD) Stock Chart | Relmada Therapeutics Inc. posts 103% EPS miss vs estimatesReal Trader Network - UBND thành phố Hải Phòng

Apr 23, 2026

Apr 22, 2026

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - qz.com

Apr 22, 2026

Apr 21, 2026

Relmada Therapeutics Inc erwartet einen Verlust von 70 Cents pro AktieEarnings Preview - TradingView

Apr 21, 2026

Apr 20, 2026

Relmada Therapeutics (RLMD) Stock: Solid Choice? (Breakout Watch) 2026-04-20Investment Picks - Xã Châu Thành

Apr 20, 2026

Apr 17, 2026

Relmada (NASDAQ: RLMD) details 2025 turnaround, seeks share and plan increases - Stock Titan

Apr 17, 2026

Apr 16, 2026

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3%Here's What Happened - MarketBeat

Apr 16, 2026

Apr 16, 2026

Relmada Therapeutics shares jump 25% after promising bladder cancer trial results - MSN

Apr 16, 2026

Apr 14, 2026

Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus

Apr 14, 2026

Apr 14, 2026

Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN

Apr 14, 2026

Apr 14, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 14, 2026

Apr 13, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat

Apr 13, 2026

Apr 11, 2026

Form PRE 14AOther preliminary proxy statements - ADVFN

Apr 11, 2026

Apr 10, 2026

[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan

Apr 10, 2026

Apr 10, 2026

Shorts Report: Is Relmada Therapeutics Inc a speculative investmentGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan

Apr 09, 2026

Apr 09, 2026

Relmada Therapeutics (NASDAQ:RLMD) Hits New 12-Month HighShould You Buy? - MarketBeat

Apr 09, 2026

Apr 09, 2026

Aug Update: Should I invest in Relmada Therapeutics Inc before earningsM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Volume Recap: Does Relmada Therapeutics Inc offer margin of safety2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Trade Report: Whats next for Relmada Therapeutics Inc stock2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

Mizuho reiterates Relmada stock rating on Phase 3 trial progress By Investing.com - Investing.com Australia

Apr 08, 2026

Apr 08, 2026

Mizuho reiterates Relmada stock rating on Phase 3 trial progress - Investing.com UK

Apr 08, 2026

Apr 08, 2026

Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider

Apr 08, 2026

Apr 08, 2026

Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo

Apr 08, 2026

Apr 08, 2026

Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD) - The Globe and Mail

Apr 08, 2026

Apr 06, 2026

Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan

Apr 06, 2026

Apr 06, 2026

Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget

Apr 06, 2026

Apr 06, 2026

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research

Apr 06, 2026

Apr 06, 2026

Can Relmada Therapeutics (RLMD) Stock Go Higher | Price at $6.94, Down 0.72%Investment Signal Network - Cổng thông tin điện tử Tỉnh Sơn La

Apr 06, 2026

Apr 04, 2026

RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 04, 2026

Apr 04, 2026

RLMD PE Ratio & Valuation, Is RLMD Overvalued - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan

Apr 03, 2026

Apr 03, 2026

RLMD Stock Analysis: Relmada Therapeutics Inc slips 1.55% to $6.99 in biotech trading - UBND thành phố Hải Phòng

Apr 03, 2026

Apr 02, 2026

Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK

Apr 02, 2026

Apr 02, 2026

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail

Apr 02, 2026

Apr 01, 2026

RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress

Apr 01, 2026

Mar 31, 2026

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN

Mar 31, 2026

Mar 30, 2026

Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha

Mar 30, 2026

Mar 30, 2026

With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan

Mar 30, 2026

Mar 29, 2026

Relmada wins bullish view at Piper Sandler on cancer therapy - MSN

Mar 29, 2026